A Hold recommendation has recently been issued to medical information provider The TriZetto Group, Inc. (TZIX) by Zacks information technology analyst Tom Park.  Here's what his latest update said:

'TZIX announced that management has reiterated its 2007 guidance. The company is scheduled to report Q4 results on February 4. We previously lowered our FY07 revenue and EPS estimates. Management previously raised its FY07 guidance and revealed preliminary 2008 guidance.

'In addition to strong revenue growth and expanding gross margins, earnings growth has been driven by lower SG&A due to the McKesson settlement that eliminated the associated legal costs and absent the settlement costs incurred in Q306. At its current price of $16.78 per share, TZIX is trading at roughly 24x our 2008 earnings estimate of $0.69 per share, which is at a premium to the peer group average P/E multiple of roughly 21x but almost in-line 0.9x P/E/G to the group average.

'The CareKey, PDM, and QCSI acquisitions provide the company substantial opportunities and we believe the stock continues to deserve a premium valuation. At roughly 26x our 2008 EPS estimate or around a 1x P/E/G, our price target remains at $18. Our target price is based on roughly 26x FY08 EPS estimate.'